Cigna Denied Experimental Treatment? Here's How to Appeal

Few denial reasons are more dangerous than Cigna labeling a treatment "experimental" or "investigational." This designation allows Cigna to exclude treatments that have strong scientific evidence, FDA approval, and widespread clinical use. Cigna's PxDX auto-denial algorithm flagged large categories of treatments as investigational without individual clinical review — a practice that drew national attention. If Cigna denied your treatment on experimental or investigational grounds, there is a clear legal and clinical framework for challenging that determination.

Why Cigna Denies Treatments as Experimental

Cigna's Coverage Policy Guidelines define a treatment as "experimental or investigational" when it does not meet a multi-factor test:

1. FDA approval for the specific indication being treated
2. Sufficient clinical evidence in peer-reviewed literature to support safety and efficacy
3. Acceptance as standard-of-care by qualified medical experts in the relevant specialty
4. Inclusion in recognized clinical guidelines or drug compendia

Importantly, Cigna can deny a treatment as investigational even when it has FDA approval — if the claim is that the approved treatment is being used "off-label" for an indication not in the approved labeling.

Off-label use is a major source of denials. Many FDA-approved drugs and devices are routinely used off-label in clinical practice — sometimes for indications with stronger evidence than the original approval. Oncology is the most prominent example: cancer treatment frequently involves off-label use of targeted therapies and immunotherapies based on tumor genetics. Cigna may deny these as investigational even when every major oncology guideline endorses them.

Clinical trial routine care. Cigna frequently denies treatments available only through clinical trials. This is often incorrect. Over 40 states and the ACA (Section 2709) require insurers to cover routine costs of care for patients enrolled in qualifying clinical trials — meaning standard medical costs (physician visits, labs, imaging) associated with clinical trial participation must be covered even when the trial drug itself is provided free by the trial sponsor. Cigna has been documented denying these routine care costs in violation of state and federal law.

Common Denial Reasons for Experimental/Investigational Claims

• Off-label drug use — FDA-approved drug used for an indication not in the labeling
• Lacks sufficient peer-reviewed evidence — Cigna's CPB concludes evidence is inadequate
• Not included in drug compendia — Drug not listed for this indication in DRUGDEX, Clinical Pharmacology, or similar recognized compendia
• Phase I or II trial only — Cigna requires Phase III evidence
• Conflicts with professional society consensus — Cigna asserts guidelines do not support the treatment
• Clinical trial participation — Cigna denies routine care costs for qualifying trial participants

Your Legal Rights

ACA Section 2709 — Clinical trial coverage: The ACA requires insurers to cover routine patient costs for care in qualifying clinical trials for life-threatening conditions. "Routine costs" include visits, lab tests, and imaging ordered as part of standard care — not the investigational item itself. If Cigna denied these costs, this is a direct ACA violation.

State clinical trial coverage laws: More than 40 states have clinical trial coverage laws, many broader than the federal ACA provision. Some states require coverage for all cancers, not just life-threatening conditions. Look up your state's specific statute and cite it in your appeal.

Drug compendia recognition: Most states and Medicare require coverage of off-label uses supported by recognized drug compendia (DRUGDEX, American Hospital Formulary Service Drug Information). If your drug's off-label use is listed in these compendia for your indication, Cigna may be required by state law to cover it.

NCCN Compendium: The National Comprehensive Cancer Network (NCCN) Drug and Biologics Compendium is specifically recognized by many state laws and Medicare as evidence of a medically accepted indication. If your off-label cancer drug use is in the NCCN Compendium, this is powerful legal and clinical authority.

ERISA (29 U.S.C. § 1133): For employer plans, ERISA requires Cigna to provide specific reasons for denial, the clinical criteria applied, and the right to a full and fair review. The appeals reviewer must consider all evidence you submit — including peer-reviewed literature and specialist letters.

Documentation Checklist

Before filing your appeal, gather:

• Cigna denial letter with the specific investigational classification reason
• Full text of the Cigna Clinical Policy Bulletin (CPB) applied to your denial
• FDA approval status for the drug/device — including labeling and approved indications
• Peer-reviewed literature package: Phase II and III trials, systematic reviews, meta-analyses
• Professional society clinical guideline citations (NCCN, ACR, AHA, ASH, etc.)
• NCCN Compendium listing if applicable (for oncology off-label use)
• Drug compendia listings (DRUGDEX, AHFS) if applicable
• Treating specialist letter directly rebutting the "investigational" characterization
• State clinical trial coverage statute (if enrolled in a trial)
• Documentation showing Cigna covers analogous treatments for related indications

Step-by-Step: Appeal Your Cigna Experimental Treatment Denial

Step 1: Obtain the Full Cigna Investigational Policy and Specific CPB

Request the complete text of the Clinical Policy Bulletin Cigna applied. You cannot rebut arguments you have not seen. Identify exactly which element of Cigna's multi-factor test they claim your treatment fails.

Step 2: File a Level 1 Internal Appeal Within 180 Days

This appeal must directly address each element of Cigna's investigational standard:

• FDA approval: Document the approval status. If approved for a different indication, note this — FDA approval demonstrates safety and regulatory review. Cite FDA labeling.
• Peer-reviewed evidence: Compile Phase II/III trials, systematic reviews, and meta-analyses. Summarize findings directly relevant to your diagnosis and treatment.
• Professional society guidelines: Cite NCCN, ACR, AHA, ASH, or other major specialty society guidelines that include your treatment as a recommended option. Quote the specific guideline language.
• Compendia listings: If applicable, document that the off-label use is supported by recognized compendia.
• Clinical trial routine care: If enrolled in a qualifying trial, cite ACA § 2709 and your state's clinical trial coverage statute by name.

Step 3: Obtain a Specialist Letter

Your treating specialist should write a detailed letter that:

• Describes the evidence base for the treatment — not just assertions, but specific studies
• Cites current professional society guidelines
• Explains why the "investigational" characterization is incorrect given the clinical evidence
• Addresses any specific concern raised in Cigna's CPB

Step 4: Request Peer-to-Peer Review

Your physician can request a peer-to-peer review with Cigna's medical director — a direct clinical conversation about the evidence. This is particularly effective for experimental treatment denials because the peer physician is harder to sustain an investigational classification when faced directly with published evidence from a knowledgeable specialist.

Step 5: File Level 2 Internal Appeal If Needed

If Level 1 is denied, escalate. Add any additional evidence — updated literature, new guideline citations, additional specialist opinions. Cigna must consider all new evidence submitted on appeal.

Step 6: External Independent Review

External reviewers are not bound by Cigna's internal CPB definitions of "investigational." They apply independent medical judgment about whether a treatment meets the standard of care in the relevant specialty. Overturn rates are significant at this stage for experimental treatment denials. Request external review immediately after exhausting internal appeals.

Arguments That Win Cigna Experimental Treatment Appeals

FDA approval documentation: Even for off-label use, document the FDA approval for the drug/device explicitly. FDA approval establishes a regulatory standard of safety and efficacy.

Comparable treatment argument: If Cigna covers similar treatments for related indications, document this. Cigna cannot logically classify your treatment as investigational while covering functionally identical treatments for similar patients. Request information about comparable covered treatments in your appeal.

NCCN Compendium for oncology: If your off-label cancer drug is in the NCCN Compendium, this is the single most powerful argument for reversal. Many state laws require coverage of NCCN Compendium-listed drugs. Quote the specific category and recommendation.

Expedited appeal for urgent situations: If experimental treatment is being denied for a life-threatening condition with no comparable alternative, request expedited internal review simultaneously with expedited external review. Under the ACA, Cigna must respond within 72 hours for urgent situations. Do not wait.

Fight Back With ClaimBack

Cigna's "experimental and investigational" exclusion is one of the most powerful tools insurers use to deny expensive treatments. Challenging it requires engaging with FDA law, clinical literature, specialty guidelines, and state clinical trial statutes simultaneously. ClaimBack is built for exactly this challenge — we generate a professional appeal letter in 3 minutes that directly addresses Cigna's investigational criteria.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal